News - The Clinic of Change

News

"Jornal Económico": The Brave New World of Ketamine

Clinics specializing in the treatment of mental health issues are popping up all over the world; they stand out for their use of ketamine, a hallucinogenic drug used recreationally but which, in medically controlled doses, achieves what antidepressants cannot. In Lisbon, it’s called The Clinic of Change. It treats managers and businesspeople for burnout, among other conditions.

NIHR: Recruitment for the clinical trial of ketamine-assisted psychotherapy for alcoholism

The largest trial ever to investigate whether ketamine-assisted psychotherapy can help people with alcohol addiction—a collaboration between the NIHR (the UK’s National Institute for Health and Care Research) and the Medical Research Council, and led by the University of Exeter—is currently recruiting participants.

"Público": Ketamine is already being used in five hospitals to treat treatment-resistant depression

It has been used to treat treatment-resistant depression in Portugal for about four years. São João already offers ketamine-assisted therapy.

“SAPO”: What happens to our brain during a psychedelic trip? Neuroscientist David Nutt’s answer

What happens in the brain during a psychedelic trip remains one of the great unanswered questions in neuroscience, although we know much more now than we did 15 years ago. British neuropsychopharmacologist David Nutt sheds light on this issue in the excerpt we’re publishing from his book *Psychedelics*.

"Financial Times": Could psychedelics be the solution to workplace depression?

This drug is being provided to workers through company health insurance as the popularity of psychedelic-assisted psychotherapy grows.

“Vice”: I went through psychotherapy using psychedelics, and this is how it went.

“One thing that was really important to me was feeling more present in my body and in my life throughout the entire process. I had never felt such clarity, and, like most people, I had never spent four weeks so intensely focused on understanding myself and improving myself.”

"New Scientist": The Unlikely Transformation of a Psychedelic Drug into a Mental Health Treatment.

Driven by impressive clinical trials, some companies are offering this type of therapy as a health benefit for their employees - but what are the risks of this growing popularity?

"The Standard": Denying access to psychedelics is like denying access to the COVID-19 vaccine.

Neuropsychopharmacologist and former government medicines official Professor David Nutt has become one of the leading scientists defending the right to psychedelic medicine for mental health. In this interview, he explains that the time to legalize is now.